Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: stagecancerlymphomachemotherapypatients
  Phrases that lowered it: evaluate theto evaluateaccordingand safetyefficacy and
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 13 (raises risk) · Sponsor's track record
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Disease area, dermatology: No (lowers risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Keywords listed: 0 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens NCT02533323 · started 2012 · scored riskier than 27% of active trials terminated
• Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage NCT02359162 · started 2015 · scored riskier than 17% of active trials terminated
• Sandwich Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL NCT02520479 · started 2013 · scored riskier than 33% of active trials terminated
• A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) NCT05254899 · started 2021 · scored riskier than 32% of active trials completed
• Stage I/II Nasal NK Cell Lymphoma NCT01321008 · started 2011 · scored riskier than 96% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.